| Name | Title | Contact Details |
|---|
At TruTag Technologies, we have devoted our energy and competency to developing a one-of-a-kind security solution to give brand owners the power to mitigate risks from counterfeiting and diversion in order to maintain the integrity of their brand and products. Our mission is to develop and apply cutting edge technology and innovative identification and security methods to offer the best product security platform in terms of quality, efficacy and safety for the protection of brands and consumers worldwide. We are driven to develop a full spectrum of market applications for the TruTag platform thereby making a greater impact on the prevention of counterfeiting and diversion. We have manufacturing facilities in Hawaii, engineering offices in California, and business development offices in Pennsylvania, Texas and Hong Kong. TruTag`s early technology research was funded in part by the U.S. Army Medical Research division. The company is supported by venture capital firms and strategic corporate investors.
Centura Health connects individuals, families and neighborhoods across Colorado and western Kansas with more than 6,000 physicians and 21,000 of the best hearts and minds in health care. Through our 19 hospitals, neighborhood health centers, physician practices and clinics, home care and hospice services, and Flight For Life® Colorado, our caregivers make the region`s best health care accessible. We`re on a mission to build flourishing communities and whole person care. We`re Centura Health, and we`re your dedicated health partner for life.
Innovative Cellular Therapeutics (ICT) is a private clinical stage biotechnology company headquartered in Rockville, MD. ICT is focused on the development of cellular immunotherapies for the treatment of solid tumors. ICT`s unique CoupledCAR® technology platform is designed to overcome the common challenges of treating solid tumors. ICT has achieved promising preclinical and proof-of-concept clinical results in late-stage solid tumors, such as colorectal cancer and thyroid cancer. The U.S. Food and Drug Administration (FDA) has provided a Study-May-Proceed letter for the Company`s Investigational New Drug (IND) application for a Phase 1 clinical trial of GCC19CART targeting relapsed and refractory metastatic colorectal cancer. ICT expects to initiate this U.S. focused clinical trial, referred to as CARAPIA-1, in the summer of 2022. The Company has a broad pipeline of CAR-T candidates targeting additional solid tumors.
Mega Aid is a full service specialty and compounding pharmacy, serving physicians and their patients.
Global Pharmaceutical Sourcing is a Bethesda, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.